Thank you for your interest in our Clinical Discussion Forum. Please fill out this form to register for our event.
Date: Tue, Oct 10, 2017
Time: 5:30pm: Networking, drinks and appetizers
6:30pm: Clinical presentation and dinner
Venue: Central Park Bistro
181 East 4th Ave.
San Mateo, CA 94401
Ample Parking Available in Lot behind Restaurant
Cognitive Assessment Technology: CNS and Beyond Accelerating Safety and Efficacy Studies in Drug Development
This presentation will discuss the assessment of cognitive function throughout
the drug development process for both CNS and non-CNS indications. It will
include a discussion of the current regulatory landscape, methodological
considerations for the design of clinical trials and approaches to the analysis
and interpretation of cognitive outcome measures for the evaluation of both
drug efficacy and safety.
Topics for Discussion:
- Benefits of monitoring cognition in drug development
- Methodological approach to measuring cognition
- Current regulatory landscape
- Cognitive assessment case studies
- Special populations: elderly and pediatric subjects
- New digital technologies and future directions in cognitive assessment
Kenton H. Zavitz PhD, Director of Clinical Affairs, Cambridge Cognition, Ltd.
With over 18 years of biotechnology and pharmaceutical experience, Dr. Zavitz has comprehensive experience from drug discovery and clinical development through to pre-commercialization. Previously he served as Chief Scientific Officer for the biotech Zocere Inc., developing a neuroprotectant drug. At Myriad Pharmaceuticals, Kenton worked in a variety of roles including Clinical Affairs, Chief Scientist, Director of Neurodegeneration Therapeutics Discovery and Director of Strategic In-licensing and Scientific Evaluation. Currently he serves on the Scientific Advisory Board for Exonate Limited, a biotech start-up. Kenton received his PhD in Biochemistry and Molecular Biology from The Sloan-Kettering Division of the Weill Cornell Graduate School of Medical Sciences in New York City.